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SUMMARY
Despite their known transforming properties, the effects of leukemogenic FLT3-ITD mutations on
hematopoietic stem and multipotent progenitor cells and on hematopoietic differentiation are not
well understood. We report a mouse model harboring an ITD in the murine Flt3 locus that develops
myeloproliferative disease resembling CMML and further identified FLT3-ITD mutations in a subset of
human CMML. These findings correlated with an increase in number, cell cycling, and survival of
multipotent stem and progenitor cells in an ITD dose-dependent manner in animals that exhibited
alterations within their myeloid progenitor compartments and a block in normal B cell development.
This model provides insights into the consequences of constitutive signaling by an oncogenic
tyrosine kinase on hematopoietic progenitor quiescence, function, and cell fate.INTRODUCTION
The FMS-like tyrosine kinase 3 (FLT3) gene encodes
a class III receptor tyrosine kinase (RTK) that shares strong
sequence and structural similarities to other family mem-
bers including FLT1, FMS, PDGFbR, and c-KIT (Rosnet
and Birnbaum, 1993). FLT3 plays a critical role in normal
hematopoiesis (for reviews see Gilliland and Griffin,
2002; Stirewalt and Radich, 2003), and within the hemato-
poietic system, its expression occurs primarily in imma-Cture myeloid and lymphoid progenitors, including CD34+
cells with high levels of CD117 (c-KIT) expression (Rasko
et al., 1995; Rosnet et al., 1996), but not in erythroid cells
(Gabbianelli et al., 1995), megakaryocytes (Ratajczak
et al., 1996), or mast cells (Hjertson et al., 1996). Although
targeted disruption of Flt3 results in healthy adult mice
with normal mature hematopoietic populations, these
animals demonstrate deficiencies in primitive pro-B and
pre-B cell lymphoid compartments (Mackarehtschian
et al., 1995). Moreover, bone marrow (BM) reconstitutionSIGNIFICANCE
Activating FLT3 mutations are among the most common genetic events in AML and confer a poor clinical progno-
sis. Essential to our understanding of how these lesions contribute to myeloid leukemia is the development of a
Flt3-ITD ‘‘knockin’’ murine model that has allowed examination of the consequences of constitutive FLT3 signaling
on primitive hematopoietic progenitors when expressed at appropriate physiologic levels. These animals informed
us to the existence of FLT3-ITD-positive human CMML, which has clinical importance given the availability of FLT3
small molecule inhibitors. This model will not only serve as a powerful biological tool to identify mutations that
cooperate with FLT3 in leukemogenesis, but also to assess molecular therapies that target either FLT3 or
components of its signaling pathways.ancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc. 367
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Mouse Model of Chronic Myelomonocytic Leukemiaexperiments revealed a reduced ability of cells lacking Flt3
to reconstitute both T cells and myeloid cells (Mackareht-
schian et al., 1995), together indicating an important role
for FLT3 in the development of multipotent hematopoietic
cells and lymphoid cells.
High levels of wild-type FLT3 expression have been de-
tected in a number of hematologic malignancies including
the vast majority of patients with AML (70% to >90%)
(Carow et al., 1996; Rosnet et al., 1996) and a large pro-
portion of precursor B cell acute lymphoblastic leukemia
(ALL) including a subset of ALL carrying a chromosomal
translocation involving the 11q23 locus (Armstrong et al.,
2002; Drexler, 1996; Rosnet et al., 1996). Congruent with
these findings, FLT3 is also expressed at high levels in
both leukemia and lymphoma cell lines (DaSilva et al.,
1994; Meierhoff et al., 1995) including pre-B, myeloid,
and monocytic cell lines.
Internal tandem duplications (ITD) within the juxtamem-
brane (JM) domain of FLT3 in patients with AML were first
reported in 1996 (Nakao et al., 1996) and occur in approx-
imately 25% of patients, making it one of the most single
common mutations in adult AML (Frohling et al., 2002;
Kiyoi et al., 1999; Kottaridis et al., 2001; Schnittger
et al., 2002; Whitman et al., 2001). FLT3-ITD mutations
result in ligand-independent receptor dimerization (Kiyoi
et al., 1998), constitutive FLT3 signaling, and activation
of the STAT5, RAS/MAPK, and PI3K pathways and confer
factor-independent growth to 32D and Ba/F3 cells (Haya-
kawa et al., 2000; Mizuki et al., 2000). Another major class
of FLT3 mutations that also cause constitutive FLT3 acti-
vation and induce autonomous proliferation of cytokine-
dependent cell lines occurs within the activation loop
(AL) of the second kinase domain (Yamamoto et al., 2001).
This group of mutations is comprised of substitutions,
small deletions, or insertions most commonly involving
codons 835 and 836 and is detected in approximately
5%–10% of patients with AML. More recently, AL mu-
tations in FLT3 have also been described in cases of
ALL that harbor rearrangements of the Mixed Lineage
Leukemia (MLL) gene on chromosome 11q23 (Armstrong
et al., 2003) as well as AL and ITD mutations in a small
subset of T-ALL (Paietta et al., 2004) implicating FLT3 in
the pathogenesis of both lymphoid and myeloid disease.
Although both FLT3-AL and FLT3-ITD mutations cause
constitutive activation of the receptor tyrosine kinase,
their signal transduction properties and transforming abil-
ities appear to differ considerably from one another
(Choudhary et al., 2005; Grundler et al., 2005) arguing
for differential roles of these classes of mutations in AML
pathogenesis. Lastly, a group of point mutations within
the JM domain have also recently been described in ap-
proximately 1% of AML cases involving several amino
acids including residues 579, 590, 591, 592, and 594
(Reindl et al., 2006; Stirewalt et al., 2004).
Gain-of-function mutations in FLT3, in particular FLT3-
ITD mutations, are of significant clinical consequence,
and a number of studies have shown that FLT3-ITD muta-
tions may be associated with disease progression (Horiike
et al., 1997; Ishii et al., 1999) and are associated with an368 Cancer Cell 12, 367–380, October 2007 ª2007 Elsevier Incincreased risk of relapse and shorter overall survival
(Frohling et al., 2002; Kiyoi et al., 1999; Kottaridis et al.,
2001; Schnittger et al., 2002; Thiede et al., 2002; Whitman
et al., 2001). Moreover, patients with low or absent levels
of wild-type (WT) FLT3, consistent with homozygosity for
the FLT3-ITD allele, appear to have a particularly dismal
outcome (Thiede et al., 2002; Whitman et al., 2001),
suggesting FLT3-ITD gene dosage has biologic and prog-
nostic significance.
Given their frequency and relevance to AML disease
pathogenesis and prognosis, there is a compelling basis
for understanding the role of activating FLT3 mutations
in leukemogenesis and critical to this advancement is
the development of accurate leukemogenic FLT3 animal
models. In this study, we have generated a murine model
whereby we have introduced an internal tandem duplica-
tion (ITD) mutation in the endogenous murine Flt3 locus.
This model has distinct advantages over prior retroviral
transduction and transgenic platforms employing heterol-
ogous promoters where differences in expression levels of
activated FLT3 may affect disease phenotype and avoids
potential cooperating mutations introduced by retroviral
integration (Baldwin et al., 2007; Kelly et al., 2002b; Lee
et al., 2005). Employing this model, we have explored
the biological impact of constitutive FLT3 signaling on
primitive hematopoietic stem and progenitor populations,
providing significant mechanistic insights into how FLT3-
ITD mutations contribute to myeloid leukemogenesis and
demonstrate that FLT3-ITD expression results in the de-
velopment of a fully penetrant myeloproliferative disorder
within these animals. The murine phenotype closely
resembles human chronic myelomonocytic leukemia
(CMML), and genomic analysis of a large series of primary
patient samples led to the identification of a subset of
FLT3-ITD-positive CMML. This mouse model provides
an accurate framework for understanding the biological
mechanisms governing the genesis and progression of
FLT3-associated myeloid disease. Moreover, not only can
it serve as a powerful system to identify cooperating mu-
tations with FLT3 in leukemogenesis, but it also allows
the ability to assess the therapeutic efficacy of molecular
agents that target FLT3 or downstream signaling path-
ways activated by the FLT3-ITD allele in these cooperative
models of acute leukemia.
RESULTS
Generation of a FLT3-ITD ‘‘Knockin’’ Murine Model
To better understand the role of FLT3-ITD mutations in
disease pathogenesis when expressed physiologically
from its endogenous promoter, we engineered a human
ITD (W51) (Kelly et al., 2002b) into exon 14 of the murine
Flt3 locus by homologous recombination in embryonic
stem (ES) cells (Figures 1A–1C). Correctly targeted ES
cells were used to produce viable mice carrying mutant
ITD alleles. Heterozygous (Flt3+/ITD) mice were inter-
crossed to produce homozygous Flt3ITD/ITD animals that
were viable and fertile with predicted Mendelian ratios
(data not shown). Both heterozygous and homozygous.
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Mouse Model of Chronic Myelomonocytic LeukemiaFigure 1. ‘‘Knockin’’ of an Internal Tandem Duplication Mutation in the Murine Flt3 Gene
(A) Schematic of the Flt3 locus (WT) and targeting vector (ITD) comprised of murine genomic sequences encompassing exons 11–15 and an in-frame
human W51 ITD mutation (*) within exon 14 and a neomycin resistance cassette flanked by two loxP sites (arrowheads) downsteam of exon 15.
(B) Southern blot analysis with the 50 probe of SacI-digested DNA from Flt3+/+, Flt3+/ITD, and Flt3ITD/ITD mice.
(C) PCR analysis of mouse tail DNA from Flt3+/+, Flt3+/ITD, and Flt3ITD/ITD animals.
(D) Immunoblot of Flt3 expression in primary spleen cells from mutant and WT animals. Equivalent amounts of protein were loaded from spleen protein
lysates from two independent animals with the indicated genotype and blotted with anti-Flt3 antibody.
(E) Representative flow cytometric analysis of Flt3 expression in total, live (PI negative) BM cells in Flt3+/+, Flt3+/ITD, and Flt3ITD/ITD mice. Data in bar
graph represent the percentage of Flt3 positive in total live BM cells (mean ± SEM) Flt3+/+ (n = 3), Flt3+/ITD (n = 4), Flt3ITD/ITD (n = 5) (p = NS), although the
cell numbers which express FLT3 are increased in FLT3-ITD mice, the mean fluorescence intensity range which correlates with FLT3 protein expres-
sion is similar for all 3 genotypes.
(F) Flow cytometric analysis of levels of phospho-Flt3 (p-FLT3) and phospho-Stat5 (pSTAT5) in whole BM and spleen cells from mutant mice and WT
littermate controls. Data are representative of two independent experiments.Cancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc. 369
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Mouse Model of Chronic Myelomonocytic LeukemiaFigure 2. Myelomonocytic Expansion in
Flt3+/ITD and Flt3ITD/ITD Animals Versus
Wild-Type Flt3+/+ Mice
(A) Composite data from age-matched litter-
mates of indicated genotypes in the C57BL/6
background (mean ± SEM; Flt3+/+, n = 20;
Flt3+/ITD, n = 21; Flt3ITD/ITD, n = 18) demonstrat-
ing ITD dose-dependent splenomegaly. (B)
Total white blood cell (WBC) counts and (C)
WBC differential values from age-matched lit-
termates of mutant and WT animals (mean +/
SEM). (D) Representative flow cytometric
analysis of peripheral blood from Flt3+/+,
Flt3+/ITD, and Flt3ITD/ITD mice for Gr1 and
Mac1 highlights expanded granulocytic (green)
and monocytic (red) populations, the former
exhibiting high forward (FSChi) and side (SSChi)
scatter properties and the latter exhibiting
characteristic intermediate forward (FSCint)
and side (SSCint) scatter properties. Peripheral
blood images illustrate an unremarkable smear
and lymphocyte (black arrow) in a WT animal,
but progressively increased numbers of mono-
cytes (red arrows) in mutant animals (Wright-
Giemsa; scale bars, 20 mm).animals expressed comparable levels of Flt3 protein to
wild-type (WT) littermates (Figures 1D and 1E). Compared
to WT BM and spleen cells, Flt3ITD/ITD mutant mice also
demonstrated a consistent increase in the levels of phos-
pho-Flt3 and the known downstream signaling intermedi-
ate, phospho-Stat5 (Rocnik et al., 2006). This was also
observed to a lesser degree in Flt3+/ITD animals (Figure 1F).
Flt3+/ITD and Flt3ITD/ITD Animals Develop
a Myeloproliferative Disease with
Monocytic Features
Comparative analysis of Flt3+/ITD and Flt3ITD/ITD with age-
matched WT littermates demonstrated dose-dependent
development of progressive splenomegaly (Figure 2A
and Figure S1A in the Supplemental Data available with
this article online). Mutant animals showed mildly de-370 Cancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc.creased liver size, hemoglobin levels, and platelet counts
(Figures S1A–S1D), and Flt3ITD/ITD animals exhibited sig-
nificant leukocytosis and monocytosis with a reversal of
neutrophil to lymphocyte ratios seen in both hetero- and
homozygous animals compared to Flt3+/+ WT controls
(Figures 2B and 2C). Morphologic and flow cytometric
analysis of mutant animals further confirmed the ex-
panded granulocyte (Gr1+/Mac1+/FSChi/SSChi) and mono-
cyte (Gr1/lo/Mac1+/FSCint/SSCint) populations in their
peripheral blood (PB) (Figure 2D). Histopathology de-
monstrated an expansion of splenic red pulp in mutant
animals comprised mainly of mature myeloid and ad-
mixed erythroid elements as well as a marked white pulp
expansion by cells resembling maturing monocytes.
These cells were also present in mutant BM and livers in
a background of increased numbers of maturing myeloid
Cancer Cell
Mouse Model of Chronic Myelomonocytic Leukemiaforms (Figure 3A) and exhibited variably positive nonspe-
cific esterase (NSE), but negative sudan black B (SBB)
staining, confirming their monocytic nature (Figure 3D).
Flow analysis of mutant BM and spleens demonstrated
significantly increased mature myeloid (Gr1+/Mac1+) and
monocytic (Gr1/lo/Mac1+/F4-80+) populations as well as
immature (Mac1+//ckit+) cells versus WT controls (Fig-
ure 3B and data not shown), which were accompanied
by a concomitant decrease in the percentage of B and T
lymphoid cells (Figure 3B). These findings were supported
by B220, CD3, and Mac1 immunohistochemistry of
mutant and WT spleens, which also demonstrated an
absence of staining for MPO, CD34, and Mac3 within
the expanded splenic white pulp (Figure 3C and data not
shown). Additional analysis of the B cell population indi-
cated that there was a significant loss of mature B cells
(B220+IgM+; data not shown) in both the BM and the
spleen from mutant animals, and further examination indi-
cated a specific block of B cell development at the pre-B
stage (B220+CD43; Figure 3E).
Flt3-ITD myeloproliferative disease, including this block
in B cell development, was transplantable into secondary
recipients as determined by spleen weight, histopatho-
logic examination, and flow cytometric studies performed
on lethally irradiated (2 3 550 rad) wild-type recipient
animals, receiving 1 3 106 BM cells from either Flt3+/+ or
Flt3ITD/ITD animals (Figure S2), at experimental endpoint,
supporting the notion that the phenotypic effects of the
ITD allele were cell autonomous.
Cell Biological and Developmental Impact of
FLT3-ITD Expression in the Hematopoietic
Stem and Progenitor Compartment
When plated in methylcellulose cultures in the presence
of growth factors, BM cells from Flt3ITD/ITD mice demon-
strated increased colony numbers overall, with propor-
tionately greater numbers of monocyte colony forming
units (CFU-M; Figure 4A and 4B) as well as fewer erythroid
burst forming units (BFU-E) and granulocyte-erythroid-
monocyte-megakarocyte units (CFU-GEMM) (Figure 4A)
compared to Flt3+/ITD and Flt3+/+ littermates. In addition,
colonies derived from Flt3+/ITD or Flt3ITD/ITD BM did not
show any enhanced serial replating activity and consis-
tently gave rise to fewer numbers of colonies in the second
round of replating (Figure 4C), demonstrating that the
ITD allele does not confer properties of self-renewal to
hematopoietic progenitors in vitro.
Evaluation of the LinSca1+ckit+ (LSK) compartment
(containing long-term and short-term HSC, as well as mul-
tipotent progenitors cells) and myeloid progenitor (Lin-
Sca1ckit+) populations of Flt3+/ITD and Flt3ITD/ITD BM
demonstrated an 2-fold increase in the number of LSK
cells (p = 0.0034) and a mild trend of increased myeloid
progenitors in Flt3ITD/ITD mice over heterozygous and WT
littermates (Figure 4D). Although total numbers of com-
mon lymphoid progenitors (CLP) and total myeloid pro-
genitors were not significantly different between geno-
types (Figure S3 and Figure 4F), the ITD allele affected
subpopulations within the myeloid progenitor compart-Cament, with an expansion in the relative percentage of
immunophenotypic granulocyte-monocyte progenitors
(GMP) and a corresponding decrease in megakaryocyte-
erythroid progenitors (MEP) (Figure 4D), consistent with
the myeloproliferative phenotype observed in the mice
and enhanced CFU-M and reduced BFU-E. We also ob-
served significantly reduced size and numbers of CFU-S
in mice transplanted with Flt3ITD/ITD LSK compared with
WT LSK (Figure 4G). As CFU-S activity typically reflects
primitive multipotent progenitors or ST-HSCs with con-
siderable megakaryocyte-erythroid potential, these obser-
vations further support the erythroid potential of ST-HSCs
being negatively affected in Flt3ITD/ITD mice.
Analysis of the effects of the Flt3-ITD allele on cell cycle
of LSK and myeloid progenitor compartments demon-
strated an ITD dose-dependent increase in the proportion
of LSK cells in S/G2/M with a corresponding decrease in
the proportion in G0/G1 (Figures 5A and 5B). This effect
appeared specific to LSK cells as no discernible differ-
ences in cell-cycle distributions were detected in myeloid
progenitors from WT and mutant animals (Figures 5A and
5C). In contrast, both LSK and myeloid progenitor popula-
tions demonstrated an ITD dose-dependent decrease in
the number of cells undergoing apoptosis (Figures 5D–
5F), suggesting that constitutive FLT3 signaling confers
differential proliferative and antiapoptotic effects within
these two compartments. Similar results in cell-cycle, sur-
vival, stem cell, and progenitor analyses were observed in
a younger cohort of animals (1 month) (Figure S4), further
supporting the cell-intrinsic nature of the effects conferred
by the ITD allele in these animals.
FLT3-ITD Mutations Are Present in a Subset of
Human CMML
FLT3 mutations have been primarily found in patients with
AML. However, the hematopoietic phenotype resembling
human CMML that was observed in our murine model, the
fact that approximately 20% of CMML patients develop
secondary AML (Fenaux et al., 1988; Onida et al., 2002),
and the high prevalence of FLT3 mutations in myelomono-
cytic and monocytic variants of de novo AML (subtypes
M4 and M5 according to the French-American-British
[FAB] classification) (Kottaridis et al., 2001; Schnittger
et al., 2002; Thiede et al., 2002) led us to hypothesize
that activating FLT3 mutations may also be present in pa-
tients with CMML. We therefore analyzed BM samples
from 194 patients with newly diagnosed CMML for the
presence of FLT3-ITD mutations and FLT3-AL mutations
involving codons D835 and I836. This analysis identified
FLT3-ITD mutations in 6 (3.1%) of 194 cases (Table 1).
Of the 6 FLT3 mutant patients, 4 presented with ‘‘prolif-
erative CMML,’’ as defined by the FAB classification,
which was associated with constitutional symptoms,
involvement of extramedullary organs (hepatomegaly,
splenomegaly, pleural effusion; Table 2), anemia requiring
transfusions, and thrombocytopenia. Furthermore, 5 of
the 6 FLT3 mutant cases had a short (less than 3 months)
history of an antecedent hematologic disorder. Kaplan-
Meier plots indicated that the median survival of CMMLncer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc. 371
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Mouse Model of Chronic Myelomonocytic LeukemiaFigure 3. Flt3+/ITD and Flt3ITD/ITD Mice Develop a Chronic Myeloproliferative Disease with a Prominent Monocytic Component
(A) Histopathologic sections of spleen, bone marrow (BM), and liver from representative Flt3+/+ (+/+), Flt3+/ITD (+/ITD), and Flt3ITD/ITD (ITD/ITD) animals
in the C57BL/6 background. Splenic red pulp is expanded largely by maturing myeloid and erythroid elements in both hetero- and homozygous
animals that also display a prominent white pulp expansion comprised largely of intermediate sized cells with moderate amounts of pale cytoplasm
(monocytes) compared to the normal small lymphocyte populations seen in WT control white pulp (spleen: first row [H&E; scale bars, 500 mm], second
row [H&E; scale bars, 50 mm]). Clusters of morphologically similar pale cells are observed in BM and liver of Flt3ITD/ITD mice in a background of
significant maturing myeloid hyperplasia (also seen in heterozygous animals to a lesser degree) when compared with unremarkable BM from WT372 Cancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc.
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Mouse Model of Chronic Myelomonocytic Leukemiapatients with FLT3-ITD (8.5 months) was shorter than that
of CMML patients with FLT3 wild-type (18.2 months) (p =
0.09, log-rank test; Figure 6). Univariate Cox proportional
hazards models confirmed a significant association of
FLT3-ITD with survival (p = 0.021, hazard ratio (HR) =
2.66, 95% confidence interval (CI) 1.56–6.13), however
such an association was not significant in a multivariate
Cox model, presumably due to limited cohort size.
Demographic information and comprehensive labora-
tory data were available for 168 of the 194 patients (Table
S1). While no appreciable differences were observed in
the majority of parameters, we noted that median WBC
counts and serum LDH levels were modestly higher in
FLT3 mutant patients than in patients with FLT3 wild-
type. Although small sample size precluded attainment of
statistically significant WBC and LDH parameters available
for FLT3-ITD (n = 6) with those of FLT3 wild-type (n = 185),
comparison between these two groups displayed trends
for increased frequency of features associated with pro-
liferative type CMML (FAB classification) (including an ab-
normal elevated LDH > 700 U/l, WBC count > 13.03 109/l,
and the presence of organomegaly) in FLT3-ITD positive
versus FLT3 wild-type patients (data not shown).
FLT3-ITD-associated CMML displayed no evidence of
eosinophilia in both human cases and in our murine model
(Table S2) unlike CMML associated with PDGFRb fusion
proteins. Chromosome banding analysis revealed normal
cytogenetics in 4 of the 6 FLT3 mutant cases, whereas the
remaining 2 cases exhibited a complex karyotype and
isolated monosomy 7, respectively. Of note, none of the
6 FLT3 mutant cases carried a mutation in K-RAS or
N-RAS, as compared to 38 (20.2%) of the 188 cases of
the FLT3 wild-type patients (Table 1).
DISCUSSION
Murine models of activating tyrosine kinase mutations and
fusion proteins implicated in leukemia provide instructive
platforms to examine their effects in vivo. While informa-
tive, the use of retroviral transduction or transgenic sys-
tems employing exogenous promoters in many of these
models precludes accurate physiologic expression levels
of these oncogenes and may ultimately affect the resultant
biological and phenotypic outcome (Ren, 2004). This con-
cept is supported in results from prior bone marrow trans-Cplant studies (Kelly et al., 2002b), and transgenic animals
modeling activated FLT3 mutations including our vav
FLT3-ITD mice (Lee et al., 2005) and a recently reported
Tel-FLT3 model (Baldwin et al., 2007), wherein the expres-
sion of a constitutively activated FLT3 in the form of a
Tel-FLT3 fusion protein is driven by an exogenous cyto-
megalovirus (CMV) promoter. While all of these models
have provided valuable insights into FLT3-mediated leu-
kemogenesis, the variable phenotypes observed among
these aforementioned systems support the notion that
promoter choice (e.g., FLT3-ITD: vav and LTR; Tel-FLT3:
CMV) plays an important role in both the nature and sever-
ity of disease phenotype.
To more precisely assess the effects of activated FLT3
expression at more appropriate physiologic levels, we
have generated a murine model in which expression of
a constitutively activated form of the FLT3 tyrosine kinase
is under the control of the endogenous murine Flt3 pro-
moter, representing, to our knowledge, one of the few
‘‘knockin’’ leukemogenic tyrosine kinase models.
Examination of these animals has revealed insights into
the in vivo effects on immature hematopoietic stem and
progenitor cell populations of the FLT3-ITD, one of the
most common activating tyrosine kinase mutations im-
plicated in leukemia. Our murine data demonstrate that
the leukemogenic properties conferred by FLT3-ITD are
due, in part, to increased multipotent stem and progenitor
cell cycling and enhanced survival properties within these
compartments. These findings are supported by recent
lentiviral-based FLT3-ITD expression studies in human
hematopoietic stem and progenitor cells that reported in-
creased survival and proliferation in FLT3-ITD transduced
human cell populations (Li et al., 2007).
While enhanced cell survival was observed in both
FLT3-ITD-positive myeloid progenitor (LinSca1ckit+)
and more primitive LSK (LinSca1+ckit+) populations con-
taining long-term and short-term HSC, as well as multipo-
tent progenitors cells, increased cell cycling appeared
specific to the LSK population (Figure S5). Interestingly,
this LSK-specific cell-cycle aberrancy is nearly identical
to that observed in triply null FoxO1, FoxO3, FoxO4 ani-
mals when conditionally deleted in the hematopoietic sys-
tem (Tothova et al., 2007). Prior reports have demon-
strated that activated FLT3 receptor signaling induces
phosphorylation of FoxO family members (FoxO3a) incontrols displaying normal maturing trilineage hematopoiesis (BM: first row [H&E; scale bars, 200 mm], second row [H&E; scale bars, 50 mm]; Liver
[H&E; scale bars, 200 mm; insets, 60 mm]).
(B) Flow cytometric analysis of single cell suspensions of BM and spleen of representative Flt3+/+ (+/+), Flt3+/ITD (+/ITD), and Flt3ITD/ITD (ITD/ITD) mice
demonstrates a progressive increase in both mature granulocytic (Gr1+/Mac1+) and monocytic (Gr1/lo/Mac1+) populations as well as immature
myelomonocytic (Mac1+//ckit+) cells with a corresponding decrease in the amount of B (B220+) and T (CD3+) lymphoid cell populations.
(C) Immunohistochemistry staining of paraffin-embedded spleen sections from Flt3+/+and Flt3ITD/ITD mice for B220, CD3, and Mac1 illustrate similar
reductions in the B and T lymphoid populations and an expanded Mac1 population in mutant versus WT control, respectively, for both Flt3+/+and
Flt3ITD/ITD mice. Scale bars; 500 mm (black); 50 mm (white). Stains for myeloperoxidase (MPO) highlight increased myeloid populations confined within
splenic red pulp of homozygous mutant animals.
(D) Cytospins of BM cells from Flt3ITD/ITD mice demonstrates variably weak (black arrows; third panel) to strong (red arrowheads; third panel) staining
of the expanded monocyte population [first panel: red arrows, Wright-Giemsa (W-G)] for napthol AS-D chloroacetate esterase (third panel: NSE), but
negative staining for sudan black B (middle panel: red arrows, SBB). Scale bars, 20 mm.
(E) Flow cytometric analysis of percentage (mean ± SEM) of pre-proB (CD43+/B220+), proB (CD43+/CD19+), and preB (CD43/B220+) cells in BM and
spleen from Flt3+/+, Flt3+/ITD, and Flt3ITD/ITD mice indicates an ITD allelic dose-dependent block at the preB stage of development.ancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc. 373
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Mouse Model of Chronic Myelomonocytic LeukemiaFigure 4. Colony-Forming Assays and Hematopoietic Stem Cell and Progenitor Analysis of Mutant Flt3 Animals
(A) BM cells from Flt3+/+, Flt3+/ITD, and Flt3ITD/ITD mice were plated on M3434 methylcellulose medium (containing SCF, IL-3, IL-6, EPO) and scored for
colony formation 7–10 days later (G, granulocyte; M, macrophage; GM, granulocyte macrophage; BFU-E, burst-forming unit-erythroid; GEMM, gran-
ulocyte, erythroid, macrophage, megakaryocyte). Results are the average of three independent experiments performed in duplicate (mean ± SEM are
shown).
(B) Morphology of increased numbers of CFU-M colonies [left panel, scale bar, 500 mm; middle panel; scale bar, 200 mm, right panel; scale bar, 100 mm
(Wright-Giemsa)].
(C) Bone marrow cells harboring the mutant Flt3-ITD allele do not demonstrate serial replating capability and exhibit a dose-dependent decreased
replating potential capacity. Results presented are the mean ± SEM of two independent experiments performed in duplicate.
(D–F) Multiparameter flow cytomery demonstrates significantly increased numbers of LinSca1+ckit+ cells and a trend toward increased myeloid pro-
genitors in Flt3ITD/ITD mice over heterozygous and WT animals with a progressive increase in the relative proportions of granulocyte-monocyte374 Cancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc.
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Mouse Model of Chronic Myelomonocytic LeukemiaBa/F3 cells, with resultant nuclear exclusion of FoxO pro-
teins and transcriptional repression of FoxO-target genes
critical to normal cell survival and proliferation (Brandts
et al., 2005; Scheijen et al., 2004). Taken together, our
data suggest that enhanced cell proliferation within the
LSK compartment of our mutant FLT3 mice is mediated,
at least in part, through inactivation of the FoxO transcrip-
tion factor family, although we have not formally examined
if there are alterations among FoxO family members within
these mice.
Our studies also illustrate that constitutive signaling by
FLT3-ITD at physiologic levels directs hematopoietic dif-
ferentiation toward the myeloid/monocytic lineage with
concomitant suppression of megakaryocyte-erythroid
development (Figure S5). Moreover, while the levels of
common lymphoid progenitors (CLP) appear largely indis-
cernible between mutant FLT3 animals and their wild-type
littermates, constitutive FLT3 signaling appears to induce
a block in normal B cell development, which is consistent
with the prevalence of FLT3-ITD mutations associated
with acute myeloid versus acute lymphoid leukemia. This
finding is also intriguing given the fact that absence of
Flt3 also leads to deficiencies in normal B cell develop-
ment, indicating that constitutive FLT3-ITD signaling likely
interferes with normal FLT3 gene function (Mackareht-
schian et al., 1995).
The phenotypic consequences of the aforementioned
alterations in hematopoietic stem and progenitor cell pop-
ulations results in a chronic MPD in Flt3+/ITD and Flt3ITD/ITD
animals resembling human CMML, which prompted us
to look for the presence of activating FLT3 mutations in
patient samples. Our findings along with previous reports
(Lin et al., 2006; Pardanani et al., 2003), indicate that
although the incidence of FLT3 mutations is relatively un-
common in chronic MPD, in the instances where isolated
FLT3 lesions in chronic MPD are detected, these patients
may frequently present with CMML. Although it would be
premature to conclude that CMML with FLT3-ITD is a
‘‘unique’’ subtype of this disease that is associated with
particular clinical and laboratory features at the current
time, our data suggest that this molecular feature may
represent an independent negative prognostic factor in
CMML. Clearly, analysis of larger cohorts will need to be
examined to see whether this notion bears out in multivar-
iate analysis models. Importantly, however, our findings
support that molecular assessment for the presence of
FLT3 mutations should be performed in individuals with
CMML, as their survival may be improved by inhibition of
FLT3-ITD with available small molecule compounds,
which have shown efficacy in AML (Smith et al., 2004;
Stone et al., 2005; Wadleigh et al., 2005). As imatinib me-
sylate has demonstrated considerable clinical efficacy in
the small subset of CMML associated with PDGFRb rear-Crangements involving chromosome 5q31–q33 (Apperley
et al., 2002; David et al., 2007), similar effects might be
predicted with the use of available FLT3 small molecule
inhibitors in patients with FLT3-ITD associated CMML.
The disease phenotype findings in prior FLT3 murine
models (Baldwin et al., 2007; Kelly et al., 2002a, 2002b;
Lee et al., 2005) and our current ‘‘knockin’’ model suggest
that in patients with isolated FLT3 mutations, progression
to AML is unlikely in the absence of preexisting or the
subsequent development of additional genetic lesions.
These data also suggest that subsequent mutations must
complement constitutive FLT3 activation to ensure full
transformation of hematopoietic cells and that certain
combinations of mutations are not only cooperative but
also interdependent in the pathogenesis of AML (Fig-
ure S5). Our model will serve as a valuable biological
tool to explore the individual contributions of these differ-
ent classes of leukemogenic mutations in the develop-
ment of AML and molecular therapeutic regimens that
target them.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Gene targeting and chimera formation were used to generate an ITD
‘‘knockin’’ allele in exon 14 of the murine Flt3 locus. A high fidelity
PCR-based cloning strategy was employed to construct a targeting
vector encompassing intronic murine genomic sequences upstream
of exon 11 and downstream of exon 15 and harboring previously de-
scribed human internal tandem duplication (ITD) mutation W51 (Kelly
et al., 2002b) in exon 14 and a neomycin (NEO) selection cassette
flanked by two loxP sites downstream of exon 15 at theAvrII restriction
site (Figure 1A). In brief, W51 results in duplication of human FLT3
amino acids 596–602 (R-E-Y-E-Y-D-L). Human exon 14 DNA se-
quences harboring the W51 mutation were cloned from pGEM-FLT3
W51 (Kelly et al., 2002b) by PCR as a BstXI-AvaI fragment that was
subsequently subcloned into murine exon 14 between the BstXI and
AvaI restriction sites. All intronic sequences (including splice acceptor
and donor sites), exons, and the W51 ITD mutation were verified by
DNA sequencing. Correctly targeted ES cells were confirmed by
Southern blot using probes lying beyond the regions of homology
contained within the targeting vector, and chimeric mice were subse-
quently generated by standard methods (Brigham and Women’s Hos-
pital Transgenic Core Facility). Germline transmission of the ITD allele
was achieved by crossing highly chimeric mice to wild-type C57BL/6
or Balb/c mice. Analyses were performed on animals in both the
C57BL/6 and Balb/c background which showed similar phenotypes
overall (data not shown). All data displayed in this report are from
animals in the C57BL/6 background. Flt3+/ITD and Flt3ITD/ITD and WT
littermate mice were genotyped by PCR with primers Flt314F (50-AGG
TACGAGAGTCAGCTGCAGATG-30) and Flt314R (50-TGTAAAGATGG
AGTAAGTGCGGGT-30 ) using the following parameters: 95C for
2 min, followed by 35 cycles of 95C for 1 min, 60C for 1 min, and
72C for 50 s. Animals were monitored two to three times a week for
the presence of disease by general inspection and palpation. Periph-
eral blood was collected from the retro-orbital cavity using an EDTA-
treated glass capillary and automated total and differential blood cell
counts were determined using Hemavet 950 (Drew Scientific).progenitors (GMP) in these mice. Plotted in (E) and (F) are the values from two independent experiments (mean ± SEM; Flt3+/+, n = 5; Flt3+/ITD, n = 6;
Flt3ITD/ITD, n = 6).
(G) Spleen colony forming unit (CFU-S) ability is diminished in Flt3ITD/ITD HSC (LinSca1+ckit+) cells. Duplicate WT C57BL/6 recipient mice were trans-
planted with 500 LinSca1+ckit+ cells sorted from two independent Flt3+/+ or Flt3ITD/ITD donor mice and spleens from representative recipient animals
are shown. Frequency of CFU-S is calculated as 1/(no. cells transplanted/no. colonies observed).ancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc. 375
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Mouse Model of Chronic Myelomonocytic LeukemiaFigure 5. Effects of Activated Flt3 Expression on Cell-Cycle Distribution and Survival Within Multipotent Hematopoietic Stem and
Progenitor Cell Compartments
(A–C) Multiparameter flow cytometry of primitive stem and progenitor (LinSca1+ckit+) and myeloid progenitor (LinSca1ckit+) populations demon-
strate an LSK-specific increase of cells in S/G2/M and proportional decrease in G0/G1 in an ITD dose-dependent manner. (B and C) Representative
cell cycle data from one of two independent experiments (mean ± SEM; Flt3+/+, n = 3; Flt3+/ITD, n = 3; Flt3ITD/ITD, n = 3; differences were statistically
significant in both independent experiments, Student’s t test).
(D–F) Survival analysis of HSC (LinSca1+ckit+) and myeloid progenitor (LinSca1ckit+) cells show a dose-dependent decrease in the percentage of
apoptotic cells (7-AAD/Annexin-V+) in both compartments. (E and F) Representative apoptosis data from one of two independent experiments
(mean ± SEM; Flt3+/+, n = 3; Flt3+/ITD, n = 3; Flt3ITD/ITD, n = 3; differences were statistically significant in both independent experiments, Student’s
t test).376 Cancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc.
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Mouse Model of Chronic Myelomonocytic LeukemiaCollected blood was also used to prepare blood smears, which were
stained with Wright and Giemsa. Following sacrifice, mice were exam-
ined for the presence of tumors or other abnormalities, and organs
were collected for further cell and histopathologic analysis. Single
cell suspensions were made from hematopoietic organs, washed;
red blood cells were lysed (Puregene) and frozen in 10% dimethylsulf-
oxide/90% fetal bovine serum (FBS) until analysis. All mice were
housed in a pathogen-free animal facility in microisolator cages, and
experiments were conducted with the ethical approval of the Harvard
Medical Area Standing Committee on Animals.
Flow Cytometry and Expression Analysis
For multiparameter flow cytometry, bone marrow mononuclear cells
were isolated from age-matched littermates between 1–4 months of
age backcrossed to C57BL/6 at least six generations and were flushed
from hind leg bones with RPMI (Cambrex, Biowhittaker) + 10% FCS
(GIBCO) + Penicillin/Streptomycin (Cambrex, Biowhittaker), lysed on
ice with red blood cell lysis solution (Puregene), and washed in PBS
(GIBCO) + 2% FBS. HSC (LSK), CMP, GMP, MEP, and CLP popula-
tions were analyzed and sorted using a FACSAria instrument (Becton
Dickinson, Mountain View, CA) as previously reported (Akashi et al.,
2000; Kondo et al., 1997). Apoptosis was determined by staining
freshly harvested bone marrow mononuclear cells with lineage,
stem, and progenitor markers, followed by Annexin-V and 7-AAD
staining. Cell-cycle analysis was carried out as previously reported
(Cheng et al., 2000). Additional analyses were carried out on a 4-color
FACSCalibur cytometer (Becton Dickinson, Mountain View, CA) using
samples that were washed with PBS and 0.1% bovine serum albumin
(BSA, Sigma), blocked with Fc-block (BD-PharMingen) for 10 min, and
stained with the following monoclonal antibodies that were conjugated
to either PE, FITC, PerCP, or APC: Gr-1, Mac-1, c-kit, F4/80, CD3,
B220, IgM, CD45.1, CD45.2 in PBS + 0.1% BSA for 30 min. Viable cells
were assessed with staining for 7-AAD. Antibodies for phospho-FLT3
(pFLT3) and phospho-Stat5 were obtained from Cell Signaling, and
Table 1. Mutations Identified in CMML Patients
Mutation No. of patients1 Percentage (%)
FLT3-ITD2 6 3.1
FLT3-AL3 0 0
N-RAS, K-RAS 38 19.6
FLT3-ITD and N-RAS/K-RAS mutations identified were
mutually exclusive.
1 Total number of patients analyzed (n = 194).
2 ITD, internal tandem duplication.
3 AL, activation loop.Cflow cytometry was carried out on permeabilized and fixed murine
bone marrow and spleen cells as previously described(Wernig et al.,
2006). A minimum of 10,000 events was acquired and analyzed using
CellQuest and FlowJo software. Immunoblot expression analysis for
murine Flt3 protein on primary bone marrow and spleen cells was
carried out as previously described (Lee et al., 2005) using anti-Flt3
rabbit polyclonal antibody (M20) (Santa Cruz Biotechnologies).
Colony-Forming Assays
Myeloid colony-plating assays were performed in methylcellulose-
based medium (M3434) containing 3 U/ml erythropoietin, 10 ng/ml
recombinant murine interleukin-3 (rmIL-3), 10 ng/ml rmIL-6, and 50
ng/ml rmSCF (Stem Cell Technologies, Vancouver, BC, Canada). For
primary methylcellulose cultures, 13 104 or 13 105 cells were seeded
in duplicate and scored for colony formation 7–10 days later. Serial
replating was carried out as previously described (Deguchi et al.,
2003) in three independent experiments with 104 cells replated in
duplicate for each round of replating and colony counts performed on
Figure 6. Kaplan-Meier Survival Plots of FLT3-ITD-Positive
versus FLT3 Wild-Type Patients with CMML
Survival data available from 193 newly diagnosed patients with CMML
at the M.D. Anderson Cancer Center (MDACC) were plotted, including
FLT3-ITD positive (n = 6) and FLT3-ITD negative (wild-type FLT3;
n = 187) patients. FLT3-ITD positive patients exhibited a median
survival time of 8.5 months compared to 18.2 months for FLT3 wild-
type CMML patients (p = 0.09093; log-rank analysis). Median survival
times and statistical analyses were calculated using STATISTICA data
analysis software.Table 2. Characteristics of CMML Patients with FLT3-ITD Mutations
UPIN WHO MDAPS Karyotype N-, K-RAS Organ Involve. Cause of Death
5886 CMML-2 Int-2 45,XX,-13[1]* WT pleura, liver progressive disease
4536 CMML-1 Int-1 46,XY WT spleen progressive disease
1883 CMML-1 Int-1 46,XX WT none AML, sepsis
7054 CMML-1 Int-2 46,XY WT liver, spleen cardiac, post chemo
1339 CMML-1 Int-2 46,XY WT liver, spleen progressive disease
0729 CMML-1 Int-1 7 WT none AML, sepsis
UPIN, unique patient identifier number); WHO, World Health Organization classification (CMML-1 or 2); MDAPS, M.D. Anderson
Prognostic Scoring System based upon a 4-scale system of Low, Intermediate-1 (Int-1), Intermediate-2 (Int-2), or High (Beran
et al., 2007; Onida et al., 2002); N-, K-RAS = genotypic status.
* 42–46,XX,+1,3,7,8,del(1)(q21q42),t(6;11)(q21;q23),del(7)(p22),+mar[20].ancer Cell 12, 367–380, October 2007 ª2007 Elsevier Inc. 377
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Mouse Model of Chronic Myelomonocytic Leukemiaday 7. For CFU-S assays, 500 HSC (LinSca1+ckit+) cells were sorted
from BM harvested on a FACSAria instrument (Becton Dickinson,
Mountain View, CA) from two Flt3+/+ or Flt3ITD/ITD littermate mice
each and injected into lateral tail veins of lethally irradiated WT C57/
BL6 recipient mice in duplicate. Day 12 CFU-S assay was carried
out as previously described (Morrison and Weissman, 1994).
Histopathology, Immunohistochemistry
and Cytochemistry analysis
Tissues were fixed for at least 72 hr in 10% neutral buffered formalin
(Sigma), dehydrated in alcohol, cleared in xylene, and infiltrated with
paraffin on an automated processor (Leica Bannockburn, IL, USA).
Tissue sections (4 mm thick) were placed on charged slides, deparaffi-
nized in xylene, rehydrated through graded alcohol solutions, and
stained with hematoxylin and eosin (H&E). Immunohistochemistry
was performed on paraffin-embedded tissue sections using primary
antibodies to B220 (PharMingen), myeloperoxidase (MPO; Dako),
CD3 (Dako), and Mac1 (AbCam). Cytochemical staining for Napthol
AS-D Chloroacetate Esterase (NSE) (Sigma-Aldrich) and Sudan Black
B (SBB) (Sigma-Aldrich) were performed on cytospin preparations
from bone marrow cells according to manufacturer’s protocols.
Sample Collection and DNA Sequence Analysis
Bone marrow samples from 194 patients with chronic myelomonocytic
leukemia (CMML) were collected from the M.D. Anderson Cancer
Center between 1999 and 2005 and analyzed for both internal tandem
duplication (ITD) and activation loop (AL) mutations. PCR amplification
and DNA sequencing of exons 14 and 20 of human FLT3 was per-
formed using M13-tailed primer as previously described (Levine
et al., 2005). Sequence analysis of bidirectional sequence traces was
performed using Mutation Surveyor version 2.28 (SoftGenetics, State
College, PA, USA). Candidate mutations were reamplified and se-
quenced from original DNA for independent verification. Studies in-
volving patient samples were approved by the M.D. Anderson Ethics
Committee and all subjects gave informed consent in accordance
with the Declaration of Helsinki.
Supplemental Data
The Supplemental Data include five supplemental figures and two
supplemental tables and can be found with this article online at
http://www.cancercell.org/cgi/content/full/12/4/367/DC1/.
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